{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:03:23Z","timestamp":1756339403345,"version":"3.44.0"},"reference-count":24,"publisher":"BMJ","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[1995,9]]},"abstract":"<jats:p>In 1976 we heralded the introduction of bromocriptine (Parlodel - Sandoz) as \"an important advance\" for the treatment of patients with hyperprolactinaemia.1 Now two new drugs are available for treating hyperprolactinaemia; cabergoline (\u25bcDostinex - Pharmacia) which the manufacturer claims offers \"a significant advance in prolactin control\" and quinagolide (\u25bcNorprolac - Sandoz) for which the claim is of a \"significant advance in the therapy of hyperprolactinaemia\". Do these newer products hold real advantages?<\/jats:p>","DOI":"10.1136\/dtb.1995.33965","type":"journal-article","created":{"date-parts":[[2007,10,19]],"date-time":"2007-10-19T11:54:35Z","timestamp":1192794875000},"page":"65-67","source":"Crossref","is-referenced-by-count":0,"title":["New drugs for hyperprolactinaemia"],"prefix":"10.1136","volume":"33","member":"239","published-online":{"date-parts":[[1995,9,1]]},"reference":[{"key":"2025082701461501000_33.9.65.1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/dtb.14.9.33","article-title":"Bromocriptine - An important advance","volume":"14","year":"1976","journal-title":"DTB"},{"key":"2025082701461501000_33.9.65.2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1471-0528.1995.tb09090.x","article-title":"Prolactinomas: present day management","volume":"102","author":"Soule","year":"1995","journal-title":"Brit J Obstet Gynaecol"},{"key":"2025082701461501000_33.9.65.3","first-page":"321","article-title":"CV 205-502: A new long-acting drug for inhibition of prolactin hypersecretion","volume-title":"Clin Endocrinol","volume":"26","author":"Rasmussen","year":"1987"},{"key":"2025082701461501000_33.9.65.4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jcem-63-4-941","article-title":"Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients","volume":"63","author":"Ferrari","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2025082701461501000_33.9.65.5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-63-4-941"},{"key":"2025082701461501000_33.9.65.6","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-65-3-541"},{"key":"2025082701461501000_33.9.65.7","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-66-1-193"},{"key":"2025082701461501000_33.9.65.8","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-69-4-725"},{"key":"2025082701461501000_33.9.65.9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"2025082701461501000_33.9.65.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311403"},{"key":"2025082701461501000_33.9.65.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6789.1367"},{"key":"2025082701461501000_33.9.65.12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0028-2243(91)90101-P","article-title":"CV205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia","volume":"40","author":"van der Heijden","year":"1991","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025082701461501000_33.9.65.13","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(91)90101-P"},{"key":"2025082701461501000_33.9.65.14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.74.3.577"},{"key":"2025082701461501000_33.9.65.15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2265.1990.tb00495.x","article-title":"CV205-502, a new non-ergot dopamine agonist reduces prolactinoma size in man","volume":"33","author":"Barnett","year":"1990","journal-title":"Clin Endocrinol"},{"key":"2025082701461501000_33.9.65.16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1210\/jcem-72-5-1136","article-title":"The efficacy and tolerability of CV205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients intolerant to bromocriptine","volume":"72","author":"van der Lely","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2025082701461501000_33.9.65.17","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-72-5-1136"},{"key":"2025082701461501000_33.9.65.18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF03344963","article-title":"A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinaemic patients","volume":"17","author":"Giusti","year":"1994","journal-title":"J Endocrinol Invest"},{"key":"2025082701461501000_33.9.65.19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage","volume":"13","author":"Bevan","year":"1992","journal-title":"Endocr Rev"},{"key":"2025082701461501000_33.9.65.20","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-13-2-220"},{"key":"2025082701461501000_33.9.65.21","first-page":"675","volume-title":"Lancet","volume":"342","year":"1993"},{"key":"2025082701461501000_33.9.65.22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/01443618909151142","article-title":"Carbergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient","volume":"10","author":"Page","year":"1989","journal-title":"J Obstet Gynecol"},{"key":"2025082701461501000_33.9.65.23","first-page":"349","article-title":"Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility","volume":"101","author":"Jones","year":"1994","journal-title":"J Obstet Gynecol"},{"key":"2025082701461501000_33.9.65.24","first-page":"385","article-title":"Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: A double-blind study","volume-title":"Acta Endocrinol","volume":"125","author":"Verhelst","year":"1991"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.1995.33965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:46:27Z","timestamp":1756284387000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.1995.33965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,9]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[1995,9,1]]},"published-print":{"date-parts":[[1995,9]]}},"alternative-id":["10.1136\/dtb.1995.33965"],"URL":"https:\/\/doi.org\/10.1136\/dtb.1995.33965","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[1995,9]]}}}